Mantle‑Cell Lymphoma (MCL)
Mantle‑Cell Lymphoma (MCL) is a subtype of B‑cell non‑Hodgkin lymphoma that frequently harbours the t(11;14) translocation, leading to overexpression of CYCLIN D1 and BCL‑1.
Mantle‑Cell Lymphoma is a form of non‑Hodgkin lymphoma with a diffuse pattern of small and medium lymphocytes and small cleaved cells. The disease accounts for ~5% of adult non‑Hodgkin lymphomas and is most often driven by a t(11;14) translocation that causes over‑expression of CYCLIN D1 (BCL‑1).
Understanding the genetic drivers and therapeutic options for MCL guides prognostication, treatment selection, and the development of targeted therapies.
Bizonyítékszint: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Kapcsolódó jelek
- Diffuse Large B‑Cell Lymphoma – Global Clinical Trial Landscape (2024)
- Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
- Inhibition of autoantigen‑induced B‑cell receptor (BCR) internalization as a therapeutic strategy in diffuse large B cell lymphoma (DLBCL)
- Successful treatment of primary refractory DLBCL/HGBL - MYC/BCL2 transformed from FL using glofitamab: a case report
- Loncastuximab in high‑risk and heavily pre‑treated relapsed/refractory diffuse large B‑cell lymphoma: a real‑world analysis from 21 US centers